Table 2.
The sites of initial disease progression after response to gefitinib
| Site | No. of patients | % |
| Primary lesion | 8 | 29.6 |
| Metastatic lesion | ||
| Intrapulmonary | 8 | 29.6 |
| Pleural effusion | 6 | 22.2 |
| Bone | 5 | 18.5 |
| CNS | 3 | 11.1 |
| Others | 0 | 0 |
CNS, central nervous system
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.